•  1
    Thyroid carcinoma, version 2.2014
    with R. M. Tuttle, R. I. Haddad, D. W. Ball, D. Byrd, P. Dickson, Q. -Y. Duh, H. Ehya, M. Haymart, C. Hoh, J. P. Hunt, A. Iagaru, F. Kandeel, P. Kopp, D. M. Lamonica, W. M. Lydiatt, J. McCaffrey, J. F. Moley, L. Parks, C. D. Raeburn, J. A. Ridge, M. D. Ringel, R. P. Scheri, J. P. Shah, S. I. Sherman, C. Sturgeon, S. G. Waguespack, T. N. Wang, L. J. Wirth, and K. G. Hoffmann
    These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other ki…Read more
  • Kant's Theory of Moral Agency
    Dissertation, State University of New York at Stony Brook. 2002.
    This dissertation is a reconstruction of the theory of agency implicit in Immanuel Kant's practical philosophy, and the relationship between this theory of agency and the grounds of Kant's ethical system. Beginning with an account of the state of both philosophical ethics and agency in pre-Kantian German metaphysics , chapter one examines the fundamental concept of the agent adopted by Kant in his critical philosophy. I argue that, although the concept of the agent is similar in both the theoret…Read more
  •  203
    Methodism, peace and war, 1932-45
    Bulletin of the John Rylands Library 85 (1): 147-167. 2003.